Latest press releases
- David Brennan to retire as AstraZeneca’s Chief Executive Officer
- 26 April 2012
- AstraZeneca PLC First quarter results 2012
- 26 April 2012
- AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease
- 25 April 2012
- AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout
- 23 April 2012
- FORXIGA (dapagliflozin) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
- 20 April 2012
- AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio
- 2 April 2012
- US DISTRICT COURT FINDS SEROQUEL XR® FORMULATION PATENT VALID AND INFRINGED
- 30 March 2012
- US court denies preliminary injunction application against the FDA and dismisses AstraZeneca’s lawsuit without prejudice
- 26 March 2012
- UK court finds SEROQUEL XR® formulation patent invalid
- 22 March 2012
Executive biographies
Louis Schweitzer is our Board Chair. He was appointed to this position on 11 March 2004.
Our Chief Executive Officer is David Brennan. He was appointed to this position on 1 January 2006.
Photo library
AstraZeneca tweets
-
Video: Andrew Hughes provides insight into AZ’s #collaboration with @CR_UK to fight #cancer http://t.co/nGHdGArt
18 May -
AZ #collaborating with @CR_UK on #research into new lung #cancer drug combination http://t.co/nQxnsOQJ
18 May -
RT @medimmune: Clinical-stage collaboration: Agreement between @AstraZeneca / @MedImmune and @Amgen means stronger pipelines for all...
16 May
Fast facts
AstraZeneca is a global, innovation-driven biopharmaceutical business. We focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.
Our innovative medicines are used by millions of patients worldwide.